- Home
- SBMT vs DERM Comparison
SBMT vs DERM Comparison
Compare SBMT & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBMT | DERM |
|---|---|---|
| Founded | N/A | 2014 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.0M | 190.3M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SBMT | DERM |
|---|---|---|
| Price | $8.16 | $7.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.67 |
| AVG Volume (30 Days) | 89.6K | ★ 174.9K |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.72 |
| EPS | ★ 0.31 | N/A |
| Revenue | N/A | ★ $61,858,000.00 |
| Revenue This Year | N/A | $39.72 |
| Revenue Next Year | N/A | $63.24 |
| P/E Ratio | $25.97 | ★ N/A |
| Revenue Growth | N/A | ★ 10.20 |
| 52 Week Low | $5.75 | $4.31 |
| 52 Week High | $9.48 | $9.56 |
Technical Indicators
Market Signals| Indicator | SBMT | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 44.00 | 46.58 |
| Support Level | $6.03 | $5.92 |
| Resistance Level | $8.00 | $7.39 |
| Average True Range (ATR) | 0.48 | 0.38 |
| MACD | -0.13 | -0.04 |
| Stochastic Oscillator | 0.58 | 4.55 |
Price Performance
Historical ComparisonAbout SBMT Silver Bow Mining Corp. Common Shares
Silver Bow Mining Corp is engaged in the acquisition, exploration, and development of mineral resource properties in Butte, Montana, USA. The Company's primary business objective is to identify and evaluate prospective properties with the potential for future extraction and commercialization.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.